29/10/2021at 15:47

GN Hearing's CEO regards new OTC regulation positively

The framework for the future over-the-counter sales channel in the US extends beyond what CEO Gitte Aabo had anticipated. Overall, she is pleasantly surprised.

BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

The framework of the upcoming US sales channel for over-the-counter (OTC) hearing aids was recently made public, and the big hearing aid manufacturers have been reading the over 100-page document from the US Food and Drug Administration carefully.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Hearing aid manufacturers unconcerned about potential OTC disruptions
For subscribers
Gitte Aabo nominated for Danish leadership award
For subscribers
Few weeks after downgrade: GN Hearing maintains guidance

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

The Danish dermatology company’s hand eczema candidate, delgocitinib, met all endpoints in late-stage testing.

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Pharma & biotech

Wegovy prescriptions in the US grow for another week

For subscribers

DNB surprised by GN's lack of backup plan

The lack of support for GN’s scrapped capital raise was to be anticipated, says a DNB analyst, meaning it would have made sense to make a plan B in advance.

For subscribers

Foto: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers

Pharma & biotech

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers